• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge.探索中国的Castleman病：白细胞介素-6治疗前时代及知识进展
Lancet Reg Health West Pac. 2023 Mar 24;34:100747. doi: 10.1016/j.lanwpc.2023.100747. eCollection 2023 May.
2
Multicentric IL-5-positive Castleman Disease With Nephrotic Syndrome Relapsed After Rituximab Treatment.多中心 IL-5 阳性 Castleman 病伴肾病综合征，利妥昔单抗治疗后复发。
In Vivo. 2023 Jan-Feb;37(1):493-497. doi: 10.21873/invivo.13105.
3
A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.一种特发性多中心 Castleman 病的新型预测模型：国际 Castleman 病联盟研究。
Oncologist. 2020 Nov;25(11):963-973. doi: 10.1634/theoncologist.2019-0986. Epub 2020 Sep 18.
4
Refractory uveitis in patient with castleman disease successfully treated with tocilizumab.托珠单抗成功治疗Castleman病患者的难治性葡萄膜炎。
Case Rep Ophthalmol Med. 2012;2012:968180. doi: 10.1155/2012/968180. Epub 2012 Nov 6.
5
The Role of Interleukin-6 in Castleman Disease.白细胞介素-6在Castleman病中的作用。
Hematol Oncol Clin North Am. 2018 Feb;32(1):23-36. doi: 10.1016/j.hoc.2017.09.003.
6
Castleman disease and TAFRO syndrome.卡斯尔曼病和 TAFRO 综合征。
Ann Hematol. 2022 Mar;101(3):485-490. doi: 10.1007/s00277-022-04762-6. Epub 2022 Jan 19.
7
Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China.与Castleman肿瘤相关的副肿瘤性天疱疮：中国副肿瘤性天疱疮常见报道的亚型。
Arch Dermatol. 2005 Oct;141(10):1285-93. doi: 10.1001/archderm.141.10.1285.
8
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.用司妥昔单抗治疗15年的特发性多中心Castleman病：一例报告
Ther Adv Hematol. 2022 Mar 2;13:20406207221082552. doi: 10.1177/20406207221082552. eCollection 2022.
9
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.一项评估 siltuximab（一种抗 IL-6 单克隆抗体）在 B 细胞非霍奇金淋巴瘤、多发性骨髓瘤或 Castleman 病患者中的安全性、耐受性、药代动力学和初步疗效的 I 期、开放性研究。
Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9.
10
A Rare Lymphoproliferative Disease: Castleman Disease.一种罕见的淋巴组织增生性疾病：Castleman 病。
Turk J Haematol. 2021 Dec 7;38(4):314-320. doi: 10.4274/tjh.galenos.2021.2021.0440. Epub 2021 Nov 1.

引用本文的文献

1
Quality of life after idiopathic multicentric Castleman disease in China: a cross-sectional, multi-center survey of patient reported outcome and caregiver reported outcome.中国特发性多中心Castleman病患者的生活质量：一项关于患者报告结局和照料者报告结局的横断面多中心调查
Orphanet J Rare Dis. 2024 Dec 19;19(1):469. doi: 10.1186/s13023-024-03450-0.

本文引用的文献

1
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.一项在中国开展的采用Castleman病协作网（CDCN）标准的Castleman病全国多中心回顾性研究。
Lancet Reg Health West Pac. 2023 Mar 24;34:100720. doi: 10.1016/j.lanwpc.2023.100720. eCollection 2023 May.
2
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.小分子抑制剂、免疫检查点抑制剂等：1991 年至 2021 年美国食品和药物管理局批准用于实体瘤的新型治疗药物。
J Hematol Oncol. 2022 Oct 8;15(1):143. doi: 10.1186/s13045-022-01362-9.
3
Comprehensive analysis of 65 patients with Castleman disease in a single center in China.中国单中心 65 例血管滤泡性淋巴结增生症患者的综合分析。
Sci Rep. 2022 May 24;12(1):8694. doi: 10.1038/s41598-022-12797-y.
4
Castleman disease.卡斯尔曼病。
Nat Rev Dis Primers. 2021 Nov 25;7(1):84. doi: 10.1038/s41572-021-00317-7.
5
Overview of Castleman disease.卡斯特曼病概述。
Blood. 2020 Apr 16;135(16):1353-1364. doi: 10.1182/blood.2019000931.
6
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.特发性多中心 Castleman 病的国际、循证共识治疗指南。
Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.
7
Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.Castleman病的临床特征与预后：185例中国患者的多中心研究
Cancer Sci. 2018 Jan;109(1):199-206. doi: 10.1111/cas.13439. Epub 2017 Dec 28.
8
Localized mediastinal lymphnode hyperplasia resembling thymoma.类似胸腺瘤的局限性纵隔淋巴结增生
Cancer. 1956 Jul-Aug;9(4):822-30. doi: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4.

Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge.

作者信息

Zhong Nian-Nian, Liu Bing, Bu Lin-Lin

机构信息

The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China.

Department of Oral & Maxillofacial Head Neck Oncology, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China.

出版信息

Lancet Reg Health West Pac. 2023 Mar 24;34:100747. doi: 10.1016/j.lanwpc.2023.100747. eCollection 2023 May.

DOI:10.1016/j.lanwpc.2023.100747
PMID:37283965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10240361/
Abstract
摘要